ZURA
Zura Bio Limited
NASDAQ · Healthcare · Biotechnology · US
$6.10
+3.74%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
Market Cap
$584.56M
MomentumView details →
1D Return
+3.74%
YTD Return
+16.41%
RSI (14)
59.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.4x
Market Cap
$584.56M
RSI (14)
59.0
MomentumView details →
1D Return
+3.74%
YTD Return
+16.41%
SummaryUpdated Jun 1, 2026
Zura Bio Limited (NASDAQ:ZURA) is a clinical-stage biotechnology company founded and based in San Diego, California. The company went public in March 2023 and focuses on developing novel therapeutic medicines to treat immune and inflammatory disorders. As a pre-revenue biotechnology firm, Zura Bio is currently advancing multiple drug candidates through clinical trials, with its lead programs targeting specific biological pathways involved in autoimmune and inflammatory diseases.
Similar companies
Latest newsMore news →
Zura Bio Limited granted inducement stock options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees on August 20, 2026, as inducements material to their employment.14d agoZura Bio Limited announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates.24d ago